Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Susmed Drops Reimbursement Request for Insomnia App
Tokyo-based med tech Susmed said on January 29 that it is withdrawing its request for the health coverage of its cognitive behavioral therapy app for insomnia, Med CBT-i, under the FY2024 reimbursement fee revision. The move comes after a healthcare…
To read the full story
Related Article
- Susmed Wins Partial Change Approval for Insomnia App, Seeks Coverage
September 8, 2025
- MHLW Panel to Further Review Positioning of Susmed’s Insomnia App
July 31, 2025
- Susmed Seeks Partial Change of Approval for Insomnia App towards Coverage
September 3, 2024
- Susmed Bags Japan Approval for Insomnia App
February 20, 2023
- Susmed’s Insomnia App in Line for Approval as Early as January
December 20, 2022
- Susmed’s Insomnia App Up for PAFSC Review on December 19
December 6, 2022
- Shionogi Gets Commercial Rights to Susmed’s Insomnia App
December 28, 2021
BUSINESS
- Daiichi Sankyo H1 Revenue Zooms 20% as ADCs Drive Growth
November 2, 2026
- Meiji Pharma Wins Defamation Suit over Kostaive Remarks
November 2, 2026
- Senju Licenses Late-Stage CRAO Drug to Kiora in Ex-Asia Deal
November 2, 2026
- Towa Pushes Back Tanabe Factory Buyout by One Month
November 2, 2026
- Fatal Drug Mix-Up Prompts Safety Alert on Two Amphotericin B Products
November 2, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…